Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: <scp>IMAGINE</scp> 2 randomized trial

Abstract

Compared with glargine at 52 weeks, peglispro resulted in a statistically superior reduction in HbA1c, more patients achieving HbA1c targets, less nocturnal hypoglycaemia, no improvement in total hypoglycaemia, higher triglyceride levels, higher aminotransferase levels, and more injection site reactions.